PolyPeptide Group shares rose after a Bloomberg report that the Swiss contract drug manufacturer attracted takeover interest from private-equity groups including Sweden's EQT and New York-based KKR.
A once messy turnaround is now being reframed as a strategic asset, and when private equity starts circling, the market stops ...
PolyPeptide Group AG shares hit the highest level in more than three years, after people with knowledge of the matter said ...
April 10 (Reuters) - Swiss contract drugmaker PolyPeptide Group AG is attracting potential takeover interest from private ...
Swiss drugmaker reviews options after takeover interest reports, highlighting early-stage discussions with no assurance of outcome ...
Swiss contract drugmaker PolyPeptide Group AG is attracting potential takeover interest from private equity firms including ...
1 This media release and key figures table include references to operational indicators and alternative financial performance measures (APM) that are not defined or specified by IFRS. These APM should ...
In H1 2025, PolyPeptide generated EUR 167.1 million in revenue, representing a 23.7% increase versus H1 2024 or a 23.3% growth at constant currency rates. Commercial revenue increased by 37.9% versus ...
MINNEAPOLIS & TORRANCE, Calif.--(BUSINESS WIRE)--Donaldson Company, Inc. (NYSE: DCI), a leading worldwide manufacturer of innovative filtration and separation products and solutions, and PolyPeptide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results